Terms: = Ovarian cancer AND TOP2A, TOP2, TP2A AND Prognosis
13 results:
1. top2a modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
2. Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.
Zhang X; Kong W; Gao M; Huang W; Peng C; Huang Z; Xie Z; Guo H
J Cell Mol Med; 2022 Jul; 26(13):3659-3674. PubMed ID: 35735060
[TBL] [Abstract] [Full Text] [Related]
3. Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with prognosis of ovarian cancer Patients.
Li X; Wang Q; Wu Z; Zheng J; Ji L
Comput Math Methods Med; 2022; 2022():5113447. PubMed ID: 35047055
[TBL] [Abstract] [Full Text] [Related]
4. Bioinformatic analysis of key pathways and genes shared between endometriosis and ovarian cancer.
Ni L; Chen Y; Yang J; Chen C
Arch Gynecol Obstet; 2022 May; 305(5):1329-1342. PubMed ID: 34727222
[TBL] [Abstract] [Full Text] [Related]
5. DFF40 deficiency in cancerous T cells is implicated in chemotherapy drug sensitivity and resistance through the regulation of the apoptotic pathway.
Kulbay M; Johnson B; Fiola S; Diaz RJ; Bernier J
Biochem Pharmacol; 2021 Dec; 194():114801. PubMed ID: 34678222
[TBL] [Abstract] [Full Text] [Related]
6. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing top2a mRNA.
Cui S; Li F
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34414458
[TBL] [Abstract] [Full Text] [Related]
7. Bioinformatics analysis of gene expression profile of serous ovarian carcinomas to screen key genes and pathways.
Fei H; Chen S; Xu C
J Ovarian Res; 2020 Jul; 13(1):82. PubMed ID: 32693821
[TBL] [Abstract] [Full Text] [Related]
8. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract] [Full Text] [Related]
9. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract] [Full Text] [Related]
10. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of top2a as a Predictive Marker for Endometrial cancer With Taxane-Containing Adjuvant Chemotherapy.
Ito F; Furukawa N; Nakai T
Int J Gynecol Cancer; 2016 Feb; 26(2):325-30. PubMed ID: 26588239
[TBL] [Abstract] [Full Text] [Related]
12. Identifying microRNA/mRNA dysregulations in ovarian cancer.
Miles GD; Seiler M; Rodriguez L; Rajagopal G; Bhanot G
BMC Res Notes; 2012 Mar; 5():164. PubMed ID: 22452920
[TBL] [Abstract] [Full Text] [Related]
13. Gene expression profiling in response to estradiol and genistein in ovarian cancer cells.
Parker LP; Taylor DD; Kesterson S; Gercel-Taylor C
Cancer Genomics Proteomics; 2009; 6(3):189-94. PubMed ID: 19487548
[TBL] [Abstract] [Full Text] [Related]
